Hexima Limited today announced additional positive results from the second part of its ongoing phase 1/2a clinical trial for HXP124 as a novel topical treatment for fungal nail infections (onychomycosis).

“These latest results confirm our interim data that HXP124 substantially reduced the area of infection in patients with a much shorter treatment period than current best-in-class therapies,” said Dr Nicole van der Weerden, Hexima’s CEO. “We now have data from a total of 36 patients treated with HXP124 and, while this sample size is still relatively small, the continued positive effect gives us confidence that HXP124 will be an effective treatment for onychomycosis with a highly differentiated value proposition and substantially shorter treatment time.”

Click here to see the full announcement.